Brooklyn, New York, August 5, 2026
Phoenix Nest Inc. has been awarded a $2,984,658 Small Business Innovation Research (SBIR) grant to support manufacturing of clinical-grade JLK-247, its investigational AAV9 gene therapy for Sanfilippo syndrome type C, also known as mucopolysaccharidosis type IIIC (MPS IIIC). The funding represents an important development milestone for the rare disease biotechnology company as it works to move JLK-247 toward clinical development for children affected by the severe inherited disorder. According to Phoenix Nest, there is currently no approved disease-modifying treatment for MPS IIIC, and the company is developing JLK-247 as a potential therapeutic approach targeting the underlying genetic disease mechanism. The new grant follows earlier support for the company’s nonclinical and clinical development activities and will specifically help finance the production of material suitable for future clinical use.
SBIR Funding Advances Clinical-Grade JLK-247 Manufacturing
The $2.98 million SBIR award, identified as grant R44NS147802, will support manufacturing of clinical-grade JLK-247, addressing a critical translational step between preclinical gene therapy research and human clinical evaluation. Manufacturing gene therapies for clinical studies requires controlled production processes capable of generating material that meets rigorous quality and regulatory requirements. For a small biotechnology company developing a treatment for an ultra-rare disease, securing funding for this stage can be particularly important because manufacturing represents a significant component of development costs. JLK-247 uses an adeno-associated virus serotype 9 (AAV9) gene therapy approach and is being developed for MPS IIIC, a rare lysosomal storage disorder that causes progressive neurological deterioration. Phoenix Nest describes the candidate as potentially becoming the first treatment for the condition, although its safety and efficacy will need to be established through clinical development before any conclusions about therapeutic benefit can be made.
FDA Designations Support Rare Disease Development Strategy
Phoenix Nest has already received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for JLK-247, providing important regulatory recognition of the candidate’s development for a serious rare pediatric disorder. These designations can support development programs targeting diseases affecting small patient populations, although they do not constitute FDA approval or demonstrate that a therapy is safe or effective. Alongside its gene therapy program, Phoenix Nest is currently recruiting patients with MPS IIIC into a natural history study at the University of Texas Southwestern in Dallas, Texas. Natural history studies can be particularly valuable in rare disease development because they provide information about disease progression, variability and clinically meaningful endpoints that can inform future interventional trial designs. Phoenix Nest has also developed C-RARE, a video recording application designed to capture activities of daily living and functional changes among patients with MPS IIIC. The company additionally highlighted emerging work around heparan sulfate as a surrogate biomarker, which could potentially contribute to measuring biological response during development.
Advertisement
Phoenix Nest Moves Rare Pediatric Gene Therapy Toward Clinic
Sanfilippo syndrome encompasses a group of inherited metabolic disorders characterized by the body’s inability to properly break down heparan sulfate, resulting in progressive accumulation that particularly affects the central nervous system. MPS IIIC is a rare subtype and can cause severe, progressive neurological symptoms during childhood. Phoenix Nest was founded by patient caregivers and scientists specifically to develop therapies for children with Sanfilippo syndrome, giving the company a highly focused rare disease development strategy. The newly awarded SBIR funding adds to previous NIH-supported projects and contributions from patient organizations supporting the company’s research. Importantly, the latest award is directed toward a tangible development requirement: producing clinical-grade AAV9 gene therapy material that could support future testing in patients. While JLK-247 remains investigational and substantial clinical and regulatory work lies ahead, successful manufacturing would represent a necessary step toward clinical evaluation. The $2.98 million federal research grant, existing FDA designations, ongoing natural history study and biomarker development efforts collectively strengthen the infrastructure surrounding the JLK-247 program. For the rare disease community, the advancement highlights continued investment in gene therapies designed for ultra-rare pediatric conditions where conventional commercial development can be challenging because of extremely small patient populations.
Source: Phoenixnestbiotech press release
